Dr. Philip M. Arlen, President and CEO, Precision Biologics, gives keynote address entitled “Preclinical/Clinical Development...
Society for the Immunotherapy of Cancer 2022 Annual Meeting, November 8 – 12, Boston, MA,...
Dr. Philip M. Arlen gives presentation “Preclinical/Clinical Development of a Neo-Epitope Targeted Monoclonal Antibody for...
Precision Biologics, Inc. and our collaborators at the NCI deliver a poster presentation at the...
Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics 2022, San...
Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, Day 1 – November...
The Phase 2 Clinical Trial with a safety lead in, combining Precision Biologics monoclonal antibody...
Dr Massimo Fantini, Director of Research is Presenting the following Talk entitled : “Stability Tests...
Precision Biologics announces that a Phase 2 Clinical Trial, combining NEO-201 with Pembrolizumab, is recruiting...
Dr. Philip M. Arlen gives scientific presentation at the 4th Annual Europe Neoantigen summit, Clinical...